Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J

This article was originally published in The Tan Sheet

Executive Summary

Bayer closes its acquisition of Merck & Co.’s consumer business, aiming to become the top OTC player and saying other consumer product acquisitions could follow. Glaxo and Novartis look to close their agreement to combine their OTC businesses in the first half of 2015.

You may also be interested in...



Taking GSK's Consumer Helm Gives McNamara View From Atop The OTC Space

Brian McNamara becomes GSK Consumer CEO after Emma Walmsley is named to succeed Andrew Witty in 2017 to run Glaxo.

Taking GSK's Consumer Helm Gives McNamara View From Atop The OTC Space

Brian McNamara becomes GSK Consumer CEO after Emma Walmsley is named to succeed Andrew Witty in 2017 to run Glaxo.

Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal

BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS107216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel